Interferon-&alpha; plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 37

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Oct 7, 2005; 11(37): 5882-5887
Published online Oct 7, 2005. doi: 10.3748/wjg.v11.i37.5882

Full Size Figure Download Figure

Figure 1 Outline of the trial

Citation: Economou M, Manolakopoulos S, Trikalinos TA, Filis S, Bethanis S, Tzourmakliotis D, Avgerinos A, Raptis S, Tsianos EV. Interferon-α plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol 2005; 11(37): 5882-5887
URL: https://www.wjgnet.com/1007-9327/full/v11/i37/5882.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i37.5882

Economou M, Manolakopoulos S, Trikalinos TA, Filis S, Bethanis S, Tzourmakliotis D, Avgerinos A, Raptis S, Tsianos EV. Interferon-α plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol 2005; 11(37): 5882-5887 [PMID: 16270403 DOI: 10.3748/wjg.v11.i37.5882]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.